CA3085661A1 - Immunostimulatory oligonucleotides - Google Patents

Immunostimulatory oligonucleotides Download PDF

Info

Publication number
CA3085661A1
CA3085661A1 CA3085661A CA3085661A CA3085661A1 CA 3085661 A1 CA3085661 A1 CA 3085661A1 CA 3085661 A CA3085661 A CA 3085661A CA 3085661 A CA3085661 A CA 3085661A CA 3085661 A1 CA3085661 A1 CA 3085661A1
Authority
CA
Canada
Prior art keywords
oligonucleotide
immunostimulatory
cholesteryl
immunostimulatory oligonucleotide
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3085661A
Other languages
English (en)
French (fr)
Inventor
Thomas Ilg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elanco Animal Health GmbH
Original Assignee
Bayer Animal Health GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health GmbH filed Critical Bayer Animal Health GmbH
Publication of CA3085661A1 publication Critical patent/CA3085661A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3085661A 2017-12-15 2018-12-07 Immunostimulatory oligonucleotides Pending CA3085661A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP17207750 2017-12-15
EP17207746.3 2017-12-15
EP17207746 2017-12-15
EP17207750.5 2017-12-15
EP17207740 2017-12-15
EP17207740.6 2017-12-15
PCT/EP2018/084019 WO2019115402A1 (en) 2017-12-15 2018-12-07 Immunostimulatory oligonucleotides

Publications (1)

Publication Number Publication Date
CA3085661A1 true CA3085661A1 (en) 2019-06-20

Family

ID=66818991

Family Applications (3)

Application Number Title Priority Date Filing Date
CA3085661A Pending CA3085661A1 (en) 2017-12-15 2018-12-07 Immunostimulatory oligonucleotides
CA3085657A Pending CA3085657A1 (en) 2017-12-15 2018-12-07 Immunostimulatory compositions
CA3085575A Pending CA3085575A1 (en) 2017-12-15 2018-12-07 Immunostimulatory oligonucleotides

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA3085657A Pending CA3085657A1 (en) 2017-12-15 2018-12-07 Immunostimulatory compositions
CA3085575A Pending CA3085575A1 (en) 2017-12-15 2018-12-07 Immunostimulatory oligonucleotides

Country Status (24)

Country Link
US (7) US11542507B2 (https=)
EP (4) EP3700564B1 (https=)
JP (5) JP7458977B2 (https=)
KR (4) KR20200099556A (https=)
CN (5) CN111801116B (https=)
AU (5) AU2018382419B2 (https=)
BR (2) BR112020011815A2 (https=)
CA (3) CA3085661A1 (https=)
CL (3) CL2020001560A1 (https=)
CO (3) CO2020007120A2 (https=)
CR (1) CR20200260A (https=)
DK (1) DK3700564T3 (https=)
DO (3) DOP2020000106A (https=)
ES (1) ES3052969T3 (https=)
IL (3) IL274975A (https=)
MX (4) MX2020006246A (https=)
PE (3) PE20210636A1 (https=)
PH (3) PH12020550904A1 (https=)
PL (1) PL3700564T3 (https=)
SG (3) SG11202004471RA (https=)
TW (3) TWI821224B (https=)
UY (3) UY38015A (https=)
WO (3) WO2019115386A1 (https=)
ZA (1) ZA202004317B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020310853A1 (en) 2019-07-05 2022-01-27 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
WO2021154745A1 (en) * 2020-01-27 2021-08-05 Oregon State University Gonorrhea subunit vaccine
CN113493790A (zh) * 2020-04-01 2021-10-12 南京华普生物技术股份有限公司 具有免疫调节功能的CpG ODN及其应用
EP3892260A1 (en) * 2020-04-10 2021-10-13 Bayer Animal Health GmbH Immunostimulatory compositions based on liposomes with zwiterionic and cationic lipids
EP4295917A3 (en) 2020-08-07 2024-02-28 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
CN112159814B (zh) * 2020-10-29 2023-05-16 中国农业科学院兰州兽医研究所 一种CpG寡聚脱氧核苷酸及制备与其用途
CN113797329A (zh) * 2021-10-19 2021-12-17 启锰生物科技(江苏)有限公司 一种二价锰佐剂和CpG佐剂的疫苗佐剂组合物及其制作方法
CN116218852A (zh) * 2023-02-22 2023-06-06 中国人民解放军陆军军医大学 一种靶向基因启动子G-四联体区域的sgRNA及其用途
CN120290549A (zh) * 2024-01-09 2025-07-11 康希诺(上海)生物研发有限公司 一种免疫刺激序列截断多聚a尾的序列构建及其应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719028A (en) * 1992-12-07 1998-02-17 Third Wave Technologies Inc. Cleavase fragment length polymorphism
ATE509102T1 (de) * 1994-07-15 2011-05-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
SK287400B6 (sk) 1999-09-25 2010-08-09 University Of Iowa Research Foundation Prostriedok s obsahom imunostimulačnej nukleovej kyseliny a jeho použitie na stimuláciu imunitnej reakcie
EP1220684B2 (en) * 1999-09-27 2010-07-14 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
KR100359753B1 (ko) * 1999-12-21 2002-11-09 주식회사 제넥신 면역조절능력 및 안전성이 증가되고 ｄＧ 연속서열이결합된 포스포다이에스터 ＣｐＧ올리고데옥시뉴클레오티드 변형체
WO2002000926A2 (en) 2000-06-30 2002-01-03 Epigenomics Ag Diagnosis of diseases associated with signal transduction
AR040996A1 (es) * 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
MXPA05013658A (es) * 2003-06-11 2006-03-02 Hybridon Inc Oligonucleotidos inmunomoduladores estabilizados.
CA2536139A1 (en) * 2003-09-25 2005-04-07 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
GEP20094767B (en) * 2003-10-30 2009-09-10 Coley Pharm Group Inc C-class oligonucleotide analogs with enhanced immunostimulatory potency
CA2543072A1 (en) * 2003-11-05 2005-06-02 Pevion Biotech Ltd. Compositions comprising melittin-derived peptides and methods for the potentiation of immune responses against target antigens
CN1250737C (zh) * 2003-11-07 2006-04-12 深圳市未来海洋科技发展有限公司 含CpG DNA畜禽疫苗佐剂的PCR制备方法
KR100558851B1 (ko) * 2004-01-08 2006-03-10 학교법인연세대학교 면역조절능력이 증가된 ＣｐＧ 올리고데옥시뉴클레오티드변형체
CN1989439B (zh) * 2004-05-06 2010-12-29 美国政府健康及人类服务部 治疗葡萄膜炎的方法以及组合物
CN101160401A (zh) * 2005-02-24 2008-04-09 科勒制药集团公司 免疫刺激寡核苷酸
EP1764108A1 (en) * 2005-09-14 2007-03-21 Gunther Hartmann Compositions comprising immunostimulatory RNA oligonucleotides and methods for producing said RNA oligonucleotides
US8114636B2 (en) * 2006-02-10 2012-02-14 Life Technologies Corporation Labeling and detection of nucleic acids
US20080045473A1 (en) 2006-02-15 2008-02-21 Coley Pharmaceutical Gmbh Compositions and methods for oligonucleotide formulations
CN100418583C (zh) * 2006-02-21 2008-09-17 朱鸿飞 预防和治疗乳腺炎的药物组合物
US20080124366A1 (en) * 2006-08-06 2008-05-29 Ohlfest John R Methods and Compositions for Treating Tumors
CN102851295B (zh) * 2006-08-28 2015-01-07 长春华普生物技术有限公司 Toll 样受体调节性寡核苷酸及其用途
NZ575437A (en) 2006-09-27 2012-02-24 Coley Pharm Gmbh Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
TR201820474T4 (tr) * 2007-08-13 2019-01-21 Zoetis Belgium S A Spesifik immün modülatör profilleri indükleyen tanımlı nükleotitler arası bağlar bağlamında rna sekansı motifleri.
JP5883381B2 (ja) 2009-05-05 2016-03-15 ミラゲン セラピューティクス，インコーポレイテッド 親油性ポリヌクレオチド接合体
BRPI1010803A2 (pt) * 2009-05-14 2018-06-12 Bayer Animal Health Gmbh "resposta imune aumentada na espécie aviária"
NZ603527A (en) 2010-05-28 2014-10-31 Zoetis Belgium S A Vaccines comprising cholesterol and cpg as sole adjuvant - carrier molecules
CN101979542B (zh) * 2010-10-28 2011-12-28 国家兽用生物制品工程技术研究中心 含CpG基序的核酸序列的制备方法及应用
UY33821A (es) 2010-12-22 2012-07-31 Bayer Animal Health Gmbh Respuesta inmune potenciada en la especie bovina
EP2471926A3 (en) 2010-12-30 2012-07-11 Intervet International BV Immunostimulatory oligodeoxynucleotides
CN103547675A (zh) * 2011-05-26 2014-01-29 英特维特国际股份有限公司 免疫刺激性寡脱氧核苷酸
US9359602B2 (en) * 2011-05-26 2016-06-07 Intervet Inc. Immunostimulatory oligodeoxynucleotides
JP6375289B2 (ja) * 2012-04-05 2018-08-15 マサチューセッツ インスティテュート オブ テクノロジー 免疫刺激組成物およびその使用方法
AR091569A1 (es) * 2012-06-28 2015-02-11 Intervet Int Bv Receptores de tipo toll
EP2922861A4 (en) * 2012-11-26 2016-09-14 Caris Life Sciences Switzerland Holdings Gmbh BIOMARKER COMPOSITIONS AND METHODS
CN105164261B (zh) * 2013-05-01 2022-03-18 莱古路斯治疗法股份有限公司 用于增强的细胞摄取的化合物和方法
TWI535451B (zh) * 2013-07-19 2016-06-01 財團法人國家衛生研究院 CpG寡去氧核苷酸、包含其之免疫組合物及組合物用於製備治療以刺激免疫反應的藥物之用途
AR097029A1 (es) * 2013-07-26 2016-02-17 Intervet Int Bv Aceleración de la respuesta inmune inducida por virus vectorial en aves, composición, uso, método para la vacunación y método para acelerar la respuesta inmune
GB2517700A (en) * 2013-08-27 2015-03-04 Lgc Ltd Oligonucleotides comprising a secondary structure and uses thereof
EP3110940A1 (en) 2014-02-28 2017-01-04 Bayer Animal Health GmbH Immunostimulatory plasmids
US10888603B2 (en) * 2016-02-12 2021-01-12 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating cancer cells expressing tumor-associated integrins

Also Published As

Publication number Publication date
WO2019115402A1 (en) 2019-06-20
RU2020122553A (ru) 2022-01-17
JP7273040B2 (ja) 2023-05-12
JP2023156485A (ja) 2023-10-24
DOP2020000107A (es) 2020-08-31
TW201936924A (zh) 2019-09-16
JP7770769B2 (ja) 2025-11-17
BR112020011838A2 (pt) 2020-11-24
CR20200260A (es) 2020-08-01
KR20200098637A (ko) 2020-08-20
JP7760560B2 (ja) 2025-10-27
EP3700564A1 (en) 2020-09-02
UY38015A (es) 2019-06-28
US20210062192A1 (en) 2021-03-04
AU2025205082A1 (en) 2025-07-31
CN111801419A (zh) 2020-10-20
CO2020007100A2 (es) 2020-06-19
IL275217A (en) 2020-07-30
AU2018382419B2 (en) 2025-04-10
MX2025007909A (es) 2025-08-01
AU2018385257A1 (en) 2020-06-18
TW201936923A (zh) 2019-09-16
KR102787688B1 (ko) 2025-03-27
WO2019115386A1 (en) 2019-06-20
US11542507B2 (en) 2023-01-03
CO2020007120A2 (es) 2020-06-19
DOP2020000106A (es) 2020-08-31
EP4647437A3 (en) 2026-02-18
BR112020011815A2 (pt) 2020-11-17
CN111801116A (zh) 2020-10-20
CN111447949B (zh) 2025-07-11
US20230174990A1 (en) 2023-06-08
US12305173B2 (en) 2025-05-20
TW201940192A (zh) 2019-10-16
DOP2020000113A (es) 2020-08-31
AU2018385256B2 (en) 2025-09-25
AU2018385256A1 (en) 2020-06-11
IL275086A (en) 2020-07-30
CO2020007102A2 (es) 2020-06-19
KR20250048594A (ko) 2025-04-09
PH12020550904A1 (en) 2021-05-17
PE20210636A1 (es) 2021-03-23
MX2020006244A (es) 2020-09-03
BR112020011845A2 (pt) 2020-11-24
CL2020001562A1 (es) 2020-11-06
WO2019115386A9 (en) 2020-07-23
CL2020001561A1 (es) 2020-11-06
AU2025204678A1 (en) 2025-07-17
ZA202004317B (en) 2023-05-31
CL2020001560A1 (es) 2020-11-06
TWI821224B (zh) 2023-11-11
MX2020006243A (es) 2020-09-03
PL3700564T3 (pl) 2026-02-23
AU2018382419A1 (en) 2020-06-04
US20250215439A1 (en) 2025-07-03
AU2018385257B2 (en) 2025-04-10
PE20210635A1 (es) 2021-03-23
JP2023153970A (ja) 2023-10-18
SG11202004773SA (en) 2020-06-29
CN111801116B (zh) 2024-11-26
EP3700564B1 (en) 2025-09-17
JP2021506779A (ja) 2021-02-22
JP7458977B2 (ja) 2024-04-01
CA3085575A1 (en) 2019-06-20
WO2019115385A1 (en) 2019-06-20
ES3052969T3 (en) 2026-01-16
JP2021506245A (ja) 2021-02-22
RU2020122545A (ru) 2022-01-19
UY38014A (es) 2019-06-28
IL274975A (en) 2020-07-30
EP4647437A2 (en) 2025-11-12
CA3085657A1 (en) 2019-06-20
US11932857B2 (en) 2024-03-19
DK3700564T3 (da) 2025-11-10
MX2020006246A (es) 2020-09-03
EP3701032A1 (en) 2020-09-02
TWI900461B (zh) 2025-10-11
US20210170020A1 (en) 2021-06-10
CN111447949A (zh) 2020-07-24
UY38016A (es) 2019-06-28
CN120519464A (zh) 2025-08-22
SG11202004471RA (en) 2020-06-29
CN119656298A (zh) 2025-03-21
US20240076681A1 (en) 2024-03-07
SG11202004952UA (en) 2020-06-29
KR20200098638A (ko) 2020-08-20
RU2020122545A3 (https=) 2022-05-04
US20200385733A1 (en) 2020-12-10
PH12020550906A1 (en) 2021-05-17
PE20200933A1 (es) 2020-09-17
JP2021506246A (ja) 2021-02-22
TWI911138B (zh) 2026-01-11
PH12020550903A1 (en) 2021-05-17
EP3694549A1 (en) 2020-08-19
KR20200099556A (ko) 2020-08-24
US20230332162A1 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
US20240076681A1 (en) Immunostimulatory oligonucleotides
AU2008203278B2 (en) Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides
JP3976742B2 (ja) インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド
CN117050986B (zh) 具有免疫刺激活性的CpG寡聚核苷酸及其用途
EP2200638A1 (en) A method of transfection and compositions therefor
IL277101B1 (en) Cpg amphiphiles and uses thereof
Miyamoto et al. Designing an immunocyte-targeting delivery system by use of beta-glucan
RU2790233C2 (ru) Иммуностимулирующие олигонуклеотиды
Wu et al. In vivo efficacy of a phosphodiester TLR-9 aptamer and its beneficial effect in a pulmonary anthrax infection model
WO2014134698A1 (en) Cpg oligonucleotide formulations and methods and uses thereof
Coffey et al. Therapeutic targeting of the innate immune system in domestic animals
Kim et al. Vaccination of rock bream, Oplegnathus fasciatus (Temminck & Schlegel), using a recombinant major capsid protein of fish iridovirus.
HK40033950A (en) Immunostimulatory oligonucleotides
Cheng et al. CpG oligodeoxynucleotide promotes protective immunity in the enteric mucosa and suppresses enterotoxigenic E. coli in the weaning piglets
Brohlin Polymeric Encapsulation of Vaccines for Enhanced Immunogenicity
Cassone et al. Cross-kingdom vaccines: dogma and heresy
Rees et al. Nonspecific Immunomodulator Therapy: CpG
Park et al. The production and immunostimulatory activity of double-stranded CpG-DNA
Zeng et al. Delivery and immunologic efficacy of CpG ODN targeting B lymphocytes of umbilical cord blood by CD40 ligand-receptor-mediated carrier*☆
HK40039985A (en) Immunostimulatory compositions
HK40045177A (en) Cpg amphiphiles and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231127

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241119

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241119

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241119

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250609

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED

Effective date: 20250825

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R11-R103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUEST RECEIVED

Effective date: 20250825

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250825

R13 Change to the name of applicant or owner recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R13-R104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250907

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251008

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251119

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251119

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251209

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251209

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251209